Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

    Not Recruiting
  • End date
    Dec 15, 2024
  • participants needed
  • sponsor
    Gilead Sciences
Updated on 27 January 2021
Gilead Study Team
Primary Contact
Meridien Research (0.0 mi away) Contact
+204 other location
systolic blood pressure
enzyme inhibitors
type 2 diabetes mellitus
ace inhibitor
diastolic blood pressure
angiotensin converting enzyme
diabetic nephropathy


The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function, reduce the risk of kidney failure, or reduce the risk of death due to kidney disease in participants with diabetic kidney disease (DKD).

Condition Diabetic Nephropathy, Nephropathy, Kidney Disease (Pediatric), Kidney Disease, Diabetic Kidney Disease
Treatment Placebo, SEL
Clinical Study IdentifierNCT04026165
SponsorGilead Sciences
Last Modified on27 January 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note